{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:59:44Z","timestamp":1792069184303,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Eli Lilly and Cmpany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic syndrome is characterized as the co-occurrence of interrelated cardiovascular risk factors, including insulin resistance, hyperinsulinemia, abdominal obesity, dyslipidemia and hypertension. Once weekly tirzepatide is approved in the US and EU for the treatment of type 2 diabetes (T2D) and obesity. In the SURPASS clinical trial program for T2D, tirzepatide demonstrated greater improvements in glycemic control, body weight reduction and other cardiometabolic risk factors versus placebo, subcutaneous semaglutide 1\u00a0mg, insulin degludec, and insulin glargine. This post hoc analysis assessed the effect of tirzepatide use on the prevalence of patients meeting the criteria for metabolic syndrome across SURPASS 1\u20135.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Metabolic syndrome was defined as having\u2009\u2265\u20093 of 5 criteria according to the US National Cholesterol Education Program: Adult Treatment Panel III. Analyses were based on on-treatment data at the primary endpoint from patients adherent to treatment (taking\u2009\u2265\u200975% study drug). A logistic regression model with metabolic syndrome status as the response variable, metabolic syndrome status at the baseline visit as an adjustment, and randomized treatment as fixed explanatory effect was used. The effect of tirzepatide use on the prevalence of patients meeting the criteria for metabolic syndrome by categorical weight loss, background medication and gender were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In SURPASS, the prevalence of patients meeting the criteria for metabolic syndrome at baseline was 67\u201388% across treatment groups with reductions at the primary endpoint to 38\u201364% with tirzepatide versus 64\u201382% with comparators. Reductions in the prevalence of patients meeting the criteria for metabolic syndrome was significantly greater with all tirzepatide doses versus placebo, semaglutide 1\u00a0mg, insulin glargine, and insulin degludec (p\u2009&lt;\u20090.001). Individual components of metabolic syndrome were also reduced to a greater extent with tirzepatide vs comparators. Greater reductions in body weight were associated with greater reductions in the prevalence of patients meeting the criteria for metabolic syndrome and its individual components. Background SGLT2i or sulfonylurea use or gender did not impact the change in prevalence of patients meeting the criteria for metabolic syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this post hoc analysis, tirzepatide at all doses studied was associated with a greater reduction in the prevalence of patients meeting the criteria for metabolic syndrome compared to placebo, semaglutide 1\u00a0mg, insulin degludec, and insulin glargine. Although more evidence is needed, these data would support greater potential improvement in cardiovascular risk factor profile with tirzepatide treatment in people across the continuum of T2D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-024-02147-9","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T12:02:08Z","timestamp":1707566528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program"],"prefix":"10.1186","volume":"23","author":[{"given":"Stephen J.","family":"Nicholls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Tof\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel W.","family":"le Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Wiese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imre","family":"Pavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govinda J.","family":"Weerakkody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meltem","family":"Zeytinoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene C.","family":"Romera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,10]]},"reference":[{"issue":"12","key":"2147_CR1","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","volume":"37","author":"GM Reaven","year":"1988","unstructured":"Reaven GM. Banting Lecture. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595\u2013607.","journal-title":"Diabetes"},{"key":"2147_CR2","doi-asserted-by":"crossref","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387(10026):1377\u201396.","DOI":"10.1016\/S0140-6736(16)30054-X"},{"key":"2147_CR3","unstructured":"National Center for Health Statistics (US). Health, United States, 2015: With Special Feature on Racial and Ethnic Health Disparities. Hyattsville (MD): National Center for Health Statistics (US); 2016. Report No.: 2016\u20131232."},{"issue":"7","key":"2147_CR4","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.2337\/diacare.28.7.1769","volume":"28","author":"ES Ford","year":"2005","unstructured":"Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28(7):1769\u201378.","journal-title":"Diabetes Care"},{"issue":"2","key":"2147_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2337\/diacare.28.2.385","volume":"28","author":"AM McNeill","year":"2005","unstructured":"McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, Ballantyne CM, Heiss G. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005;28(2):385\u201390.","journal-title":"Diabetes Care"},{"issue":"4","key":"2147_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2337\/diacare.24.4.683","volume":"24","author":"B Isomaa","year":"2001","unstructured":"Isomaa B, Almgren P, Tuomi T, Fors\u00e9n B, Lahti K, Niss\u00e9n M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683\u20139.","journal-title":"Diabetes Care"},{"issue":"1","key":"2147_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13112","volume":"22","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Jacob S. Cardiovascular outcome trials in obesity: A review. Obes Rev. 2021;22(1): e13112.","journal-title":"Obes Rev"},{"issue":"9","key":"2147_CR8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.7326\/M16-1390","volume":"166","author":"E Yu","year":"2017","unstructured":"Yu E, Ley SH, Manson JE, Willett W, Satija A, Hu FB, Stokes A. Weight history and all-cause and cause-specific mortality in three prospective cohort studies. Ann Intern Med. 2017;166(9):613\u201320.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2147_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1001\/jamacardio.2018.0022","volume":"3","author":"SS Khan","year":"2018","unstructured":"Khan SS, Ning H, Wilkins JT, Allen N, Carnethon M, Berry JD, Sweis RN, Lloyd-Jones DM. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol. 2018;3(4):280\u20137.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"2147_CR10","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1080\/07315724.2005.10719494","volume":"24","author":"IE Lofgren","year":"2005","unstructured":"Lofgren IE, Herron KL, West KL, Zern TL, Brownbill RA, Ilich JZ, Koo SI, Fernandez ML. Weight loss favorably modifies anthropometrics and reverses the metabolic syndrome in premenopausal women. J Am Coll Nutr. 2005;24(6):486\u201393.","journal-title":"J Am Coll Nutr"},{"issue":"1","key":"2147_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/ajcn\/75.1.11","volume":"75","author":"SD Poppitt","year":"2002","unstructured":"Poppitt SD, Keogh GF, Prentice AM, Williams DE, Sonnemans HM, Valk EE, Robinson E, Wareham NJ. Long-term effects of ad libitum low-fat, high-carbohydrate diets on body weight and serum lipids in overweight subjects with metabolic syndrome. Am J Clin Nutr. 2002;75(1):11\u201320.","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"2147_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1046\/j.1463-1326.2002.00236.x","volume":"4","author":"CC Case","year":"2002","unstructured":"Case CC, Jones PH, Nelson K, O\u2019Brian Smith E, Ballantyne CM. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab. 2002;4(6):407\u201314.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2147_CR13","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1210\/jc.2003-031826","volume":"89","author":"AM Xydakis","year":"2004","unstructured":"Xydakis AM, Case CC, Jones PH, Hoogeveen RC, Liu MY, Smith EO, Nelson KW, Ballantyne CM. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab. 2004;89(6):2697\u2013703.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2147_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1677\/joe.0.1710293","volume":"171","author":"AR Assali","year":"2001","unstructured":"Assali AR, Ganor A, Beigel Y, Shafer Z, Hershcovici T, Fainaru M. Insulin resistance in obesity: body-weight or energy balance? J Endocrinol. 2001;171(2):293\u20138.","journal-title":"J Endocrinol"},{"issue":"2","key":"2147_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/gerona\/58.2.M181","volume":"58","author":"BJ Nicklas","year":"2003","unstructured":"Nicklas BJ, Dennis KE, Berman DM, Sorkin J, Ryan AS, Goldberg AP. Lifestyle intervention of hypocaloric dieting and walking reduces abdominal obesity and improves coronary heart disease risk factors in obese, postmenopausal, African-American and Caucasian women. J Gerontol A Biol Sci Med Sci. 2003;58(2):181\u20139.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"3","key":"2147_CR16","first-page":"237","volume":"9","author":"D Einhorn","year":"2003","unstructured":"Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9(3):237\u201352.","journal-title":"Endocr Pract"},{"issue":"2","key":"2147_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"RR Wing","year":"2013","unstructured":"Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Barbara H, Helen PH, James OH, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145\u201354.","journal-title":"N Engl J Med"},{"issue":"11","key":"2147_CR18","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","volume":"4","author":"EW Gregg","year":"2016","unstructured":"Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, Clark JM, Coday M, Curtis JM, Egan C, Evans M, Foreyt J, Foster G, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jeffery RW, Johnson KC, Kitabchi AE, Knowler WC, Kriska A, Lang W, Lewis CE, Montez MG, Nathan DM, Neiberg RH, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Redmon B, Regensteiner J, Rejeski J, Ribisl PM, Safford M, Stewart K, Trence D, Wadden TA, Wing RR, Yanovski SZ. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4(11):913\u201321.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"17","key":"2147_CR19","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMoa1200225","volume":"366","author":"PR Schauer","year":"2012","unstructured":"Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567\u201376.","journal-title":"N Engl J Med"},{"issue":"21","key":"2147_CR20","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJMoa1401329","volume":"370","author":"PR Schauer","year":"2014","unstructured":"Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim ES, Nissen SE, Kashyap SR. Bariatric surgery versus intensive medical therapy for diabetes\u20133-year outcomes. N Engl J Med. 2014;370(21):2002\u201313.","journal-title":"N Engl J Med"},{"issue":"7","key":"2147_CR21","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1056\/NEJMoa1600869","volume":"376","author":"PR Schauer","year":"2017","unstructured":"Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, Navaneethan SD, Singh RP, Pothier CE, Nissen SE, Kashyap SR. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376(7):641\u201351.","journal-title":"N Engl J Med"},{"issue":"8","key":"2147_CR22","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.2337\/dc12-1596","volume":"36","author":"SR Kashyap","year":"2013","unstructured":"Kashyap SR, Bhatt DL, Wolski K, Watanabe RM, Abdul-Ghani M, Abood B, Pothier CE, Brethauer S, Nissen S, Gupta M, Kirwan JP, Schauer PR. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013;36(8):2175\u201382.","journal-title":"Diabetes Care"},{"issue":"10295","key":"2147_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, Kaneko S, Lee CJ, Fern\u00e1ndez Land\u00f3 L, Mao H, Cui X, Karanikas CA, Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143\u201355.","journal-title":"Lancet"},{"issue":"6","key":"2147_CR24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, Liu B, Cui X, Brown K. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"10300","key":"2147_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, Frias JP, Fern\u00e1ndez Land\u00f3 L, Brown K, Bray R, Rodr\u00edguez \u00c1. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583\u201398.","journal-title":"Lancet"},{"issue":"10313","key":"2147_CR26","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811\u201324.","journal-title":"Lancet"},{"issue":"6","key":"2147_CR27","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodr\u00edguez \u00c1. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: The SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534\u201345.","journal-title":"JAMA"},{"issue":"10402","key":"2147_CR28","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613\u201326.","journal-title":"Lancet"},{"issue":"5","key":"2147_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1210\/jendso\/bvad056","volume":"7","author":"CJ Lee","year":"2023","unstructured":"Lee CJ, Mao H, Thieu VT, Land\u00f3 LF, Thomas MK. Tirzepatide as monotherapy improved markers of beta-cell function and insulin sensitivity in type 2 diabetes (SURPASS-1). J Endocr Soc. 2023;7(5):56.","journal-title":"J Endocr Soc."},{"issue":"6","key":"2147_CR30","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","volume":"10","author":"T Heise","year":"2022","unstructured":"Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, Coskun T, Thomas MK, Mather KJ, Haupt A, Milicevic Z. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418\u201329.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2147_CR31","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","volume":"106","author":"MK Thomas","year":"2021","unstructured":"Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, Milicevic Z, Haupt A, Robins DA. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388\u201396.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2147_CR32","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","volume":"28","author":"N Sattar","year":"2022","unstructured":"Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, Zoungas S. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591\u20138.","journal-title":"Nat Med"},{"issue":"2","key":"2147_CR33","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1210\/clinem\/dgab722","volume":"107","author":"V Pirro","year":"2022","unstructured":"Pirro V, Roth KD, Lin Y, Willency JA, Milligan PL, Wilson JM, Ruotolo G, Haupt A, Newgard CB, Duffin KL. Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2022;107(2):363\u201378.","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"2147_CR34","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: An American Heart Association\/National Heart, Lung, and Blood Institute Scientific statement. Circulation. 2005;112(17):2735\u201352.","journal-title":"Circulation"},{"key":"2147_CR35","doi-asserted-by":"crossref","unstructured":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486\u201397.","DOI":"10.1001\/jama.285.19.2486"},{"issue":"Suppl 8","key":"2147_CR36","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/S0735-1097(23)02072-7","volume":"81","author":"SJ Nicholls","year":"2023","unstructured":"Nicholls SJ, D\u2019Alessio DA, Wiese RJ, Pavo I, Zeytinoglu M, Romera IC, Weerakkody GJ. Compared to insulin glargine, tirzepatide reduces the prevalence of the metabolic syndrome in patients with type 2 diabetes and high cardiovascular risk: Post-hoc analysis of SURPASS-4. J Am Coll Cardiol. 2023;81(Suppl 8):1628.","journal-title":"J Am Coll Cardiol"},{"key":"2147_CR37","doi-asserted-by":"crossref","unstructured":"Linong Ji, Andrew Ahmann, Bo Ahr\u00e9n, Matthew Capehorn, Ping Hu, Ildiko Lingvay, Wenyan Liu, Helena W. Rodbard, Zewei Shen, Christopher H. Sorli; 746-P: Semaglutide Increases the Proportion of People with T2D Achieving a Metabolic Composite Endpoint. Diabetes. 2023;72(Suppl):746\u2013P.","DOI":"10.2337\/db23-746-P"},{"issue":"Suppl 1","key":"2147_CR38","first-page":"498","volume":"65","author":"RL Batterham","year":"2022","unstructured":"Batterham RL, Holst-Hansen T, Kandler K, Rigas G, Garvey WT. Impact of once-weekly subcutaneous semaglutide 2.4 mg on metabolic syndrome in the 2-year, randomised controlled STEP 5 trial. Diabetologia. 2022;65(Suppl 1):498.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"2147_CR39","first-page":"1207","volume":"15","author":"CW le Roux","year":"2021","unstructured":"le Roux CW, Davies M, Frias JP, Jensen C, N\u00f8rkj\u00e6r Laursen P, Lingvay I, Machineni S, Varbo A, Wilding JPH, Perreault L. Once-weekly semaglutide 2.4 mg improved metabolic syndrome in adults with overweight or obesity: Post-hoc analysis of the STEP 1 trial. Obes Facts. 2021;15(Suppl 1):1207.","journal-title":"Obes Facts"},{"issue":"8","key":"2147_CR40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.clinthera.2023.06.008","volume":"45","author":"D Yu","year":"2023","unstructured":"Yu D, Shen S, Zhang J, Wang Q. Effect of the dual glucose-dependent insulinotropic peptide\/gulcagon-like peptide 1 receptor agonist tirzepatide on lipid profile and waist circumference: a systematic review and meta-analysis. Clin Ther. 2023;45(8):787\u201396.","journal-title":"Clin Ther"},{"issue":"12","key":"2147_CR41","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.2337\/dc23-1135","volume":"46","author":"MT Ma\u0142ecki","year":"2023","unstructured":"Ma\u0142ecki MT, Batterham RL, Sattar N, Levine JA, Rodr\u00edguez \u00c1, Bergman BK, Wang H, Ghimpeteanu G, Lee CJ. Predictors of \u226515% weight reduction and associated changes in cardiometabolic risk factors with tirzepatide in adults with type 2 diabetes in SURPASS 1\u20134. Diabetes Care. 2023;46(12):2292\u20139.","journal-title":"Diabetes Care"},{"issue":"10322","key":"2147_CR42","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","volume":"399","author":"I Lingvay","year":"2022","unstructured":"Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399(10322):394\u2013405.","journal-title":"Lancet"},{"issue":"11","key":"2147_CR43","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","journal-title":"Diabetes Care"},{"issue":"10120","key":"2147_CR44","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","volume":"391","author":"ME Lean","year":"2018","unstructured":"Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Stefanetti R, Trenell M, Welsh P, Kean S, Ford I, McConnachie A, Sattar N, Taylor R. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541\u201351.","journal-title":"Lancet"},{"issue":"5","key":"2147_CR45","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","volume":"7","author":"MEJ Lean","year":"2019","unstructured":"Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Welsh P, Kean S, Ford I, McConnachie A, Messow CM, Sattar N, Taylor R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019;7(5):344\u201355.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2147_CR46","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/ijo.2017.59","volume":"41","author":"GJ Ooi","year":"2017","unstructured":"Ooi GJ, Doyle L, Tie T, Wentworth JM, Laurie C, Earnest A, Cowley MA, Sikaris K, le Roux CW, Burton PR, O\u2019Brien PE, Brown WA. Weight loss after laparoscopic adjustable gastric band and resolution of the metabolic syndrome and its components. Int J Obes (Lond). 2017;41(6):902\u20138.","journal-title":"Int J Obes (Lond)"},{"issue":"Suppl 2","key":"2147_CR47","first-page":"51S","volume":"6","author":"Clinical guidelines on the identification","year":"1998","unstructured":"Clinical guidelines on the identification. evaluation, and treatment of overweight and obesity in adults\u2013The Evidence report. National Institutes of Health Obes Res. 1998;6(Suppl 2):51S-209S.","journal-title":"National Institutes of Health Obes Res"},{"issue":"7","key":"2147_CR48","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","volume":"34","author":"RR Wing","year":"2011","unstructured":"Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, Brancati FL, Peters A, Wagenknecht L. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481\u20136.","journal-title":"Diabetes Care"},{"issue":"24","key":"2147_CR49","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Torn\u00f8e CW, Ryan DH. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"key":"2147_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D\u2019Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3\u201314.","journal-title":"Mol Metab"},{"issue":"5","key":"2147_CR51","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2337\/dc22-1710","volume":"46","author":"T Heise","year":"2023","unstructured":"Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, Mather KJ, Karanikas CA, Dunn J, Haupt A, Milicevic Z, Coskun T. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care. 2023;46(5):998\u20131004.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"2147_CR52","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2337\/db22-337-OR","volume":"71","author":"K Brown","year":"2022","unstructured":"Brown K, Fernandez LL, Bergman B, Thomas MK, Liu B, Lee C. Tirzepatide improved markers of islet-cell function (fasting glucagon and HOMA2-B) and insulin sensitivity (fasting insulin and HOMA2-IR) Compared with semaglutide in people with type 2 diabetes. Diabetes. 2022;71(Suppl 1):337.","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"2147_CR53","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2337\/db22-714-P","volume":"71","author":"KJ Mather","year":"2022","unstructured":"Mather KJ, Mari A, Li J, Heise T, De Vries JH, Urva S, Coskun T, Milicevic Z, Haupt A, Thomas MK. 714-P: Greater improvement in insulin sensitivity per unit weight loss with tirzepatide compared with selective GLP-1 receptor agonism. Diabetes. 2022;71(Suppl 1):714.","journal-title":"Diabetes"},{"issue":"1","key":"2147_CR54","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12933-023-01797-5","volume":"22","author":"I Lingvay","year":"2023","unstructured":"Lingvay I, Mosenzon O, Brown K, Cui X, O\u2019Neill C, Fern\u00e1ndez Land\u00f3 L, Patel H. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovasc Diabetol. 2023;22(1):66.","journal-title":"Cardiovasc Diabetol"},{"key":"2147_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110770","volume":"202","author":"TT V\u00e1rkonyi","year":"2023","unstructured":"V\u00e1rkonyi TT, P\u00f3sa A, P\u00e1v\u00f3 N, Pavo I. Perspectives on weight control in diabetes - Tirzepatide. Diabetes Res Clin Pract. 2023;202: 110770.","journal-title":"Diabetes Res Clin Pract"},{"issue":"Suppl 1","key":"2147_CR56","first-page":"595","volume":"65","author":"T V\u00e1rkonyi","year":"2022","unstructured":"V\u00e1rkonyi T, Del Prato S, Pavo I, Nicolay C, Wiese RJ, Kahn SE. Tirzepatide reduces serum triglyceride concentrations irrespective of concomitant fibrate use in SURPASS-4 participants with type 2 diabetes at high cardiovascular risk. Diabetologia. 2022;65(Suppl 1):595.","journal-title":"Diabetologia"},{"issue":"1","key":"2147_CR57","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12933-023-01940-2","volume":"22","author":"S Sachs","year":"2023","unstructured":"Sachs S, G\u00f6tz A, Finan B, Feuchtinger A, DiMarchi RD, D\u00f6ring Y, Weber C, Tsch\u00f6p MH, M\u00fcller TD, Hofmann SM. GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease. Cardiovasc Diabetol. 2023;22(1):217.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2147_CR58","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12933-020-01174-6","volume":"19","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Verma S, Fitchett D, Ofstad AP, Lauer S, Zwiener I, George J, Wanner C, Zinman B, Inzucchi SE. Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial. Cardiovasc Diabetol. 2020;19(1):200.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"2147_CR59","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.2337\/dc06-0942","volume":"29","author":"R Bonadonna","year":"2006","unstructured":"Bonadonna R, Cucinotta D, Fedele D, Riccardi G, Tiengo A. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care. 2006;29(12):2701\u20137.","journal-title":"Diabetes Care"},{"issue":"5","key":"2147_CR60","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.2337\/diabetes.52.5.1210","volume":"52","author":"CM Alexander","year":"2003","unstructured":"Alexander CM, Landsman PB, Teutsch SM, Haffner SM. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52(5):1210\u20134.","journal-title":"Diabetes"},{"issue":"4","key":"2147_CR61","first-page":"e24469","volume":"14","author":"MA Essafi","year":"2022","unstructured":"Essafi MA, Bouabdellaoui L, Aynaou H, Salhi H, El Ouahabi H. Metabolic syndrome in patients with diabetes mellitus. Cureus. 2022;14(4):e24469.","journal-title":"Cureus."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02147-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02147-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02147-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T12:03:52Z","timestamp":1707566632000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02147-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,10]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2147"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02147-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,10]]},"assertion":[{"value":"7 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SURPASS-1, SURPASS-2, SURPASS-3, SURPASS-4, and SURPASS-5 trials were conducted in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki. All patients provided signed informed consent and protocols were approved by local ethical review boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SJN has received research support from AstraZeneca, New Amsterdam Pharma, Amgen, Anthera, Eli Lilly and Company, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and is a consultant for AstraZeneca, Amarin, Akcea, Eli Lilly and Company, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim and Vaxxinity. ST has served on advisory boards and received consulting fees from Boehringer Ingelheim, Eli Lilly and Company, Johnson and Johnson, Novo Nordisk, and Sanofi. CWlR serves on advisory boards of Novo Nordisk A\/S, Herbalife, GI Dynamics, Eli Lilly and Company, Johnson & Johnson, Glia, and Boehringer Ingelheim and was gifted stockholdings in September 2021 and divested all stock holdings in Keyron in September 2021. He continues to provide scientific advice to Keyron for no remuneration. DAD receive research support from Eli Lilly and Company and participates on the Diabetes Advisory Board for Eli Lilly and Company and the steering committee for the tirzepatide CVOT. RJW, IP, KB, GJW, MZ and ICR are employees and shareholders of Eli Lilly and Company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}